Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 170Neoplasms 66Carcinoma, Non-Small-Cell Lung 49Neoplasm Metastasis 37Unspecified Adult Solid Tumor, Protocol Specific 25Ovarian Neoplasms 21Breast Neoplasms 21Urinary Bladder Neoplasms 20Cholangiocarcinoma 20Lymphoma 19Colorectal Neoplasms 18Lymphoma, Non-Hodgkin 17Lung Neoplasms 17Sarcoma 16Hodgkin Disease 14Fallopian Tube Neoplasms 14Biliary Tract Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Gallbladder Neoplasms 11Colonic Neoplasms 11Carcinoma, Ovarian Epithelial 11Stomach Neoplasms 10Recurrence 10Solid Tumors 9Bile Duct Neoplasms 8Adenocarcinoma 8Triple Negative Breast Neoplasms 7Small Cell Lung Carcinoma 7Rectal Neoplasms 7Melanoma 7

Interventions

Amifostine 4Filgrastim 3Cyclophosphamide 3Melphalan 2Irinotecan 2Cytarabine 2Carboplatin 2spartalizumab 1sodium thiosulfate 1sargramostim 1lometrexol 1etoposide phosphate 1Vincristine 1Temozolomide 1Sirolimus 1Procarbazine 1Phenobarbital 1Peripheral Blood Stem Cell Transplantation 1Paclitaxel 1Mannitol 1Lomustine 1Interleukin-2 1Idarubicin 1Genetic Therapy 1Gemcitabine 1Folic Acid 1Fibroblast Growth Factor 7 1Fecal Microbiota Transplantation 1Drug Therapy 1Deoxycytidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Drug-Related Side Effects and Adverse Reactions × Gemcitabine × Clear all
NCT00003144 2011-03-28

Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

NYU Langone Health

Phase 1 Completed
44 enrolled

Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡